Listen
ANGIOX
-
Opinions on drugs -
Posted on
May 19 2010
- Updated on
Jun 11 2010
Reason for request
Inclusion on the list of medicines approved for use by hospitals in the extension of indication: “ANGIOX is indicated as an anticoagulant in adult patients undergoing percutaneous coronary intervention (PCI), including patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary PCI”.
-
Clinical Benefit
| Substantial |
The actual benefit of ANGIOX in this extension of the indication is substantial. |
Clinical Added Value
| no clinical added value |
ANGIOX does not provide any improvement in actual benefit (IAB level V) in comparison with the usual therapeutic management when indicated as an anticoagulant therapy in STEMI patients reperfused with primary angioplasty, given the heterogeneous nature of practice and prehospital prescription practice in France. Bivalirudin (ANGIOX) is nevertheless considered a useful additional therapeutic tool. |
English version
Contact Us
Évaluation des médicaments
